Is Leukoreduction Needed for Plasma Products?
10.17945/kjbt.2022.33.3.1 8 2
- Author:
Hee-Jeong YOUK
1
;
Yousun CHUNG
;
Hyungsuk KIM
;
Dae-Hyun KO
Author Information
1. Department of Laboratory Medicine, Kangwon National University Hospital, Kangwon National University School of Medicine, Chuncheon, Korea
- Publication Type:Letters to the Editor
- From:Korean Journal of Blood Transfusion
2022;33(3):182-184
- CountryRepublic of Korea
- Language:English
-
Abstract:
Leukoreduction is a process in which the white blood cells (WBCs) in cellular products are intentionally reduced to bring down the risk of adverse transfusion reactions, such as febrile nonhemolytic transfusion reactions or human leukocyte antigen alloimmunization. So far, Korea has not considered leukoreduction of plasma products. However there have been recommendations for leukoreduction to improve patient outcomes. The authors have experience in measuring WBCs and WBC fragment counts in plasma products and have shown that the WBC and their fragments could be efficiently removed using leukoreduction filters. Hence, it may be beneficial to begin discussions on the necessity of using leukoreduction of plasma products.
